Volume 69, Issue 9, Pages (May 2006)

Slides:

Advertisements

Similar presentations

Home care assistance and the utilization of peritoneal dialysis

Advertisements

Beta blockers in the management of chronic kidney disease

Donald R. VanDevanter, David J. Pasta, Michael W. Konstan

Volume 83, Issue 3, Pages (March 2013)

Longitudinal Estimated GFR Trajectories in Patients With and Without Type 2 Diabetes and Nephropathy Misghina Weldegiorgis, Dick de Zeeuw, Liang Li,

Volume 80, Issue 2, Pages (July 2011)

Volume 81, Issue 7, Pages (April 2012)

Volume 86, Issue 4, Pages (October 2014)

GFR Decline as an End Point for Clinical Trials in CKD: A Scientific Workshop Sponsored by the National Kidney Foundation and the US Food and Drug Administration

Response to is the reduction in urea distribution volume over time in clinically stable dialysis patients real? S. Andrulli, S. Di Filippo, F. Locatelli

The progression of chronic kidney disease: A 10-year population-based study of the effects of gender and age B.O. Eriksen, O.C. Ingebretsen Kidney International

Volume 63, Issue 4, Pages (April 2003)

Volume 66, Issue 3, Pages (September 2004)

Volume 69, Issue 2, Pages (January 2006)

Anemia as a risk factor for chronic kidney disease

Volume 82, Issue 3, Pages (August 2012)

Volume 70, Issue 11, Pages (December 2006)

Renal risk scores: Progress and prospects

D. Coyne Kidney International Volume 69, Pages S1-S3 (May 2006)

The analysis of survival data: the Kaplan–Meier method

Volume 71, Issue 6, Pages (March 2007)

Volume 70, Issue 12, Pages (December 2006)

Volume 67, Pages S48-S51 (January 2005)

Volume 65, Issue 6, Pages (June 2004)

Volume 375, Issue 9719, Pages (March 2010)

Fructose intake as a risk factor for kidney stone disease

Volume 69, Issue 12, Pages (June 2006)

Volume 69, Issue 3, Pages (February 2006)

Linda F. Fried, Trevor J. Orchard, Bertram L. Kasiske

Environmental exposure to lead and progressive diabetic nephropathy in patients with type II diabetes J.-L. Lin, D.-T. Lin-Tan, C.-C. Yu, Y.-J. Li, Y.-Y.

Volume 87, Issue 1, Pages (January 2015)

Volume 76, Issue 8, Pages (October 2009)

The kidney, a cardiovascular risk marker, and a new target for therapy

V.R. Sørensen, P.M. Hansen, J. Heaf, B. Feldt-Rasmussen

Volume 69, Issue 8, Pages (April 2006)

Higher serum C-reactive protein predicts short and long-term outcomes in peritoneal dialysis-associated peritonitis N.-Y. Zalunardo, C.-L. Rose, I.W.Y.

Volume 80, Issue 3, Pages (August 2011)

Volume 71, Issue 12, Pages (June 2007)

Volume 64, Issue 2, Pages (August 2003)

Clinical renoprotection trials involving angiotensin II-receptor antagonists and angiotensin-converting-enzyme inhibitors Barry M. Brenner, Joann Zagrobelny

Organ transplantation goes to the movies

Low triiodothyronine and survival in end-stage renal disease

Acute renal failure independently predicts mortality after myeloablative allogeneic hematopoietic cell transplant Chirag R. Parikh, Peter Mcsweeney,

Volume 70, Issue 8, Pages (October 2006)

Volume 70, Issue 7, Pages (October 2006)

Volume 60, Issue 3, Pages (September 2001)

Michael R. Lattanzio, Matthew R. Weir Kidney International

Volume 70, Issue 3, Pages (August 2006)

Volume 75, Issue 1, Pages (January 2009)

Assessing the impact of different imputation methods on serial measures of renal function: The Strong Heart Study N.-M. Shara, J.-G. Umans, W. Wang,

Volume 62, Pages S68-S72 (December 2002)

Yutaka Koda, M.D., Shin-Ichi Nishi, Masashi Suzuki, Yoshihei Hirasawa

Volume 87, Issue 3, Pages (March 2015)

Volume 70, Issue 5, Pages (September 2006)

Giuseppe Remuzzi, Carlos Chiurchiu, Piero Ruggenenti

Collecting and using patient and treatment center data to improve care: Adequacy of hemodialysis and end-stage renal disease surveillance1 William M.

Volume 70, Issue 10, Pages (November 2006)

The International Pediatric Peritonitis Registry: Starting to walk

A nationwide cohort study suggests chronic hepatitis B virus infection increases the risk of end-stage renal disease among patients in Taiwan Yi-Chun.

S. Dmitrienko, A. Yu, R. Balshaw, R.J. Shapiro, P.A. Keown

Volume 53, Issue 5, Pages (May 1998)

Associations of hemodialysis dose and session length with mortality risk in Australian and New Zealand patients M.R. Marshall, B.G. Byrne, P.G. Kerr,

Volume 57, Issue 2, Pages (October 2000)

Effect of randomized treatment on all renal events (top) and the composite of all renal events, macrovascular events, or all-cause mortality (bottom) according.

Prediction in idiopathic membranous nephropathy

Volume 60, Issue 2, Pages (August 2001)

Stephen Pastan, J. Michael Soucie, William M. McClellan

Volume 79, Issue 10, Pages (May 2011)

Rituximab treatment of idiopathic membranous nephropathy

Volume 60, Issue 1, Pages (July 2001)

Presentation transcript:

Volume 69, Issue 9, Pages 1675-1682 (May 2006) Renal risk and renoprotection among ethnic groups with type 2 diabetic nephropathy: A post hoc analysis of RENAAL D. de Zeeuw, D. Ramjit, Z. Zhang, A.B. Ribeiro, K. Kurokawa, J.P. Lash, J. Chan, G. Remuzzi, B.M. Brenner, S. Shahinfar Kidney International Volume 69, Issue 9, Pages 1675-1682 (May 2006) DOI: 10.1038/sj.ki.5000326 Copyright © 2006 International Society of Nephrology Terms and Conditions

Figure 1 Distribution of baseline albuminuria stratified by ethnic group. Each box represents albuminuria levels by quantiles. The lowest and highest boundaries below and above each box represent the 10th and 90th% quantiles, respectively. The bottom, middle, and top of each box represent the 25th, 50th, and 75th% quantiles, respectively. Kidney International 2006 69, 1675-1682DOI: (10.1038/sj.ki.5000326) Copyright © 2006 International Society of Nephrology Terms and Conditions

Figure 2 Event rate of ESRD stratified by ethnic group. The cumulative proportion (%) of patients in each ethnic group that reached ESRD was estimated using the Kaplan–Meier procedure. Kidney International 2006 69, 1675-1682DOI: (10.1038/sj.ki.5000326) Copyright © 2006 International Society of Nephrology Terms and Conditions

Figure 3 Risk for ESRD versus baseline albuminuria stratified by ethnic group. The HR with 95% CI is referenced at albuminuria <0.5 g/g in White patients. HR is controlled for all baseline risk markers summarized in the Statistical analysis section. Kidney International 2006 69, 1675-1682DOI: (10.1038/sj.ki.5000326) Copyright © 2006 International Society of Nephrology Terms and Conditions

Figure 4 Risk for ESRD versus albuminuria reduction stratified by ethnic group. The HR with 95% CI is calculated relative to 0% change in albuminuria. The HR is controlled for all risk markers at baseline and month-6 changes, summarized in the Statistical analysis section. Kidney International 2006 69, 1675-1682DOI: (10.1038/sj.ki.5000326) Copyright © 2006 International Society of Nephrology Terms and Conditions

Figure 5 Mean percent change from baseline in albuminuria over time stratified by ethnic group. Kidney International 2006 69, 1675-1682DOI: (10.1038/sj.ki.5000326) Copyright © 2006 International Society of Nephrology Terms and Conditions

Figure 6 ESRD treatment effect of losartan compared to placebo stratified by ethnic group. The dots and horizontal lines indicate HR point estimates and 95% CI's, respectively. The solid and dashed horizontal lines represent the analyses without (pre-specified) and with controlling for baseline covariates as summarized in Statistical analysis section, respectively. The vertical line indicates a reference HR of 1.0, or no difference between treatment groups. Kidney International 2006 69, 1675-1682DOI: (10.1038/sj.ki.5000326) Copyright © 2006 International Society of Nephrology Terms and Conditions